Rhone-Poulenc Rorer Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Strasbourg France (1990)
Status: Acquired by Aventis (1999) → now Sanofi-Aventis (2004)

Organization Overview

First Clinical Trial
1999
NCT00148070
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2000

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 4 Trials (1)

Key: Rhone-Poulenc Rorer (0) Acquired (1)

procaine benzylpenicillin (novocaine) (1 trial)

Drugs in Phase 3 Trials (2)

Key: Rhone-Poulenc Rorer (0) Acquired (2)

atorvastatin (lipitor) (1 trial)

levocarnitine (carnitor) (1 trial)

Drugs in Phase 2 Trials (2)

docetaxel (taxotere) (1 trial)

erythromycin (ilosone) (1 trial)

Drugs in Phase 1 Trials (5)

Key: Rhone-Poulenc Rorer (1) Acquired (4)

aldesleukin (proleukin) (1 trial)

crushed garlic clove (1 trial)

garlic powder (2 trials)

stomamycin (2 trials)

zidovudine (retrovir) (1 trial)

Drugs in Other Trials (11)

Key: Rhone-Poulenc Rorer (1) Acquired (10)

bifidobacterium lactis (1 trial)

curcuminoids (1 trial)

enoxaparin (lovenox) (1 trial)

gingerol (1 trial)

maltodextrin (1 trial)

pentamidine (pentam) (5 trials)

sc-fos (1 trial)

thiethylperazine (torecan) (1 trial)

thiocarb (2 trials)

totum-63 (1 trial)

turmeric (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 2)

Cryptosporidiosis (Phase 1)

Diarrhea (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 23
  • # of Trial APIs: 21